Owen N. Witte
Discovered the BCR-ABL kinase activity that imatinib blocks and now hunts for new prostate cancer targets.
Molecular biologist who identified the tyrosine kinase activity of the BCR-ABL oncoprotein, the basis of imatinib. His lab now defines prostate cancer lineage plasticity and targets such as PSCA and STEAP1 for immunotherapy.
Pages like this
not linked directly; found by shared links- PersonJeremie Calais
Shares UCLA Jonsson Comprehensive Cancer Center, PSMA, Prostate cancer.
- PersonBud Romine
Shares Brian Druker, BCR::ABL1 (Philadelphia chromosome), Imatinib.
- PersonCharles L. Sawyers
Shares Brian Druker, BCR::ABL1 (Philadelphia chromosome), Androgen receptor, Prostate cancer.
- PersonJohannes Czernin
Shares UCLA Jonsson Comprehensive Cancer Center, PSMA, Prostate cancer.
- TrialXALute
Shares STEAP1, Prostate cancer.
- ProductGallium-68 gozetotide (PSMA-11)
Shares UCLA Jonsson Comprehensive Cancer Center, PSMA, Prostate cancer.
- PersonRahul Aggarwal
Shares Androgen receptor, PSMA, Prostate cancer.
- PersonJanet Rowley
Shares Brian Druker, BCR::ABL1 (Philadelphia chromosome), Imatinib.